Company

Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News

Check also companies to follow in 2022 and CMN Markets for the latest stock and market trends

Novartis

Main (CRISPR) focus: Treatment of genetic blood diseases and cancer

Company stage: Clinical

Diseases: Sickle cell disease, cancer

Genome editing tool: CRISPR-Cas9, Zinc-finger nuclease, Neuro-developmental disorders

Funding stage: Public (NASDAQ:NVS)

Location: Cambridge, MA, USA (Headquarters), Basel, Switzerland

Website: https://www.novartis.com/

Pipeline: https://www.novartis.com/our-science/novartis-global-pipeline

Partners: Intellia Therapeutics, Sangamo Therapeutics

Novartis is global big pharma company. The company is mainly involved in the therapeutic development of gene-editing technologies through a partnership with Intellia Therapeutics. The two companies are co-developing a programme for the treatment of sickle cell disease, which is currently being tested in early clinical trials. The companies are also developing multiple undisclosed pre-clinical assets.

Tags

HashtagNovartis AG

Company: Novartis
close
Search CRISPR Medicine